NCT06387342

Namodenoson Treatment of Advanced Pancreatic Cancer

CF102-222PC: A Phase 2 Open-Label Study of the Safety and Activity of Namodenoson in the Treatment of Advanced Pancreatic Adenocarcinoma

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Can-Fite BioPharma · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label trial in patients with advanced pancreatic cancer. The trial will evaluate the safety, clinical activity, and pharmacokinetics of the study drug, namodenoson, in this group of patients.

Detailed description

All patients will receive the study drug twice daily. The study drug is given as a capsule, orally (by mouth). Patients will be monitored regularly for safety. Tumor imaging will be performed approximately every two months. Patients can decide to stop the treatment with study drug at any time.

Conditions

• Pancreatic Adenocarcinoma
• Pancreatic Cancer

Interventions

Type	Name	Description
DRUG	Namodenoson 25mg	oral capsule

Timeline

• Start date: 2024-11-10
• Primary completion: 2026-07-15
• Completion: 2026-12-15
• First posted: 2024-04-29
• Last updated: 2025-01-31

Locations

1 site across 1 country: Israel

Regulatory

• FDA-regulated drug study